Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis: Reply

Rheumatology

Volumn 49, Issue 9, 2010, Pages 1796-1797

  Quartuccio, Luca ^a   de Vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

DISABILITY; HUMAN; LABORATORY TEST; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 77955747978     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq142     Document Type: Letter

References (10)

1. Belmonte Serrano MA, Pincus T. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology 2010;49: 1795-6.
2. Quartuccio L, Fabris M, Salvin S et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology 2009;48:1557-9.
3. Cohen SB, Emery P, Greenwald MW et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
4. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
5. Pyrpasopoulou A, Douma S, Triantafyllou A et al. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther 2010;14:43-8.
6. Prudhomme C, Solau-Gervais E, Phillippe P et al. Rheumatoid arthritis treated with rituximab in the real life: efficacy depends on rheumatoid factor positivity but not on methotrexate association or previous treatment with anti-TNF alpha. Ann Rheum Dis 2009;68(Suppl. 3), 438.
7. van Vollenhoven RF, Chatzidionysiou K, Gabay C et al. Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the Collaborative European Registries for Rituximab in Rheumatoid Arthritis (CERERRA). Ann Rheum Dis 2009; 68(Suppl. 3), 579.
8. D'Antona G, Faustini F, Peluso G et al. B depletion in rheumatoid arthritis: clinical efficacy (Abstract in Italian). Reumatismo 2009;61:55.
9. Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2010. Advance Access Published February 25 2010, doi:10.1097/BOR.0b013e 328337bd01.
10. Fabris M, Quartuccio L, Saracco M et al. BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Ann Rheum Dis 2009;68:75.